Disease-A-Month
Volume 56, Issue 2 , Pages 72-100 , February 2010

Diagnosis and Management of Acute Ischemic Stroke

References 

  1. Kung HC, Hoyert DL, Xu J, et al. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56:1–120
  2. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics—2009 update. Circulation. 2009;119:e21–e181
  3. The National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587
  4. Gorelick AR, Gorelick PB, Sloan EP. Emergency department evaluation and management of stroke: acute assessment, stroke teams and care pathways. Neurol Clin. 2008;26:923–942
  5. Joint Commission website. http://www.jointcommission.org/CertificationPrograms/Disease-SpecificCare/DCSPM/
  6. Alberts MJ, Hademenos G, Latchaw RE, et al. Recommendations for the establishment of primary stroke centers. JAMA. 2000;283:3102–3109
  7. Stroke Units Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke (Review). Cochrane Libr 2008 http://www.cochrane.org/reviews/en/ab000197.html
  8. Lattimore SU, Chalela J, Davis L, et al. Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience. Stroke. 2003;34:e55–e357
  9. California Acute Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology. 2005;64:654–659
  10. Alberts MJ, Latchaw RE, Selman WR, et al. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke. 2005;36:1597–1618
  11. Demaerschalk BM, Durocher DL. How diagnosis-related group 559 will change the US Medicare cost reimbursement ratio for stroke centers. Stroke. 2007;38:1309–1312
  12. Schwamm LH, Holloway RG, Amarenco P, et al. A review of the evidence for the uses of telemedicine within stroke systems of care (A scientific statement from the American Heart Association/American Stroke Association). Stroke. 2009;40:2616–2634
  13. Meyer BC, Raman R, Hemmen T, et al. Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomized, blinded, prospective study. Lancet Neurol. 2008;7:787–795
  14. LaMonte MP, Cullen J, Gagliano DM, et al. Shortening time to stroke treatment using ambulance telemedicine: TeleBAT. J Stroke Cerebrovasc Dis. 2004;13:148–154
  15. Liebeskind DS. Imaging the future of stroke (I. Ischemia). Ann Neurol. 2009;66:574–590
  16. Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Circulation. 2007;115:e478–e534
  17. Thomsen HS. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States. Radiol Clin North Am. 2009;47:871–875
  18. Lyden P, Lu M, Kwiatkowski T, et al. NINDS Study Group Thrombolysis in patients with transient neurologic deficits. Neurology. 2001;57:2125–2128
  19. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA Stroke Study. Neurology. 2000;55:1649–1655
  20. The ATLANTIS, ECASS, NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–774
  21. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–1329
  22. del Zoppo GJ, Saver JL, Jauch EC, et al. American Heart Association Stroke Council Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945–2948
  23. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke (The PROACT II study: a randomized controlled trial). JAMA. 1999;282:2003–2011
  24. Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI Trial. Stroke. 2008;39:1205–1212
  25. Bose A, Henkes H, Alfke K, et al. The penumbra system: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol. 2008;29:1409–1413
  26. Josephson SA, Saver JL, Smith WS The Merci and Multi Merci Investigators. Comparison of mechanical embolectomy and intraarterial thrombolysis in acute ischemic stroke within the MCA: MERCI and Multi MERCI compared to PROACT II. Neurocrit Care. 2009;10:43–49
  27. Khatri P, Abruzzo T, Yeatts SD, et al. IMS I and II Investigators Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology. 2009;73:1066–1072
  28. Khatri P, Hill MD, Palesch YY, et al. IMS III Investigators Methodology of the Interventional Management of Stroke III Trial. Int J Stroke. 2008;3:130–137
  29. CAST (Chinese Acute Stroke Trial) Collaborative Group. Randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet. 1997;349:1641–1649
  30. Vahedi K, Hofmeijer J, Jeuttler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomized controlled trials. Lancet Neurol. 2007;6:215–222
  31. Hofmeijer J, Kappelle LJ, Amelink GJ, et al. HAMLET investigators Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomized trial. Lancet Neurol. 2009;8:326–333
  32. Castillo J, Leira R, Garcia MM, et al. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke. 2004;35:520–527
  33. Hill MD, Lye T, Moss H, et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology. 2003;60:1525–1527
  34. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–1367
  35. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57–65
  36. The NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–1297
  37. Gray CS, Hildreth A, Sandercock PA, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyhperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol. 2007;6:397–406
  38. Sherman DG, Albers GW, Bladin C, et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet. 2007;369:1347–1355
  39. Kase CS, Albers GW, Bladin C, et al. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke. 2009;40:3532–3540
  40. The Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346:549–556
  41. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346:557–563
  42. Kissela B, Schneider A, Kleindorfer D, et al. Stroke in a biracial population the excess burden among blacks. Stroke. 2007;38:2001–2023
  43. Flaherty ML, Haverbusch M, Sekar P, et al. Long-term mortality after intracerebral hemorrhage. Neurology. 2006;66:1182–1186
  44. Becker KJ, Baxter AB, Cohen WA, et al. Withdrawal of support in intracerebral hemorrhage may lead to self-fulfilling prophecies. Neurology. 2001;56:766–772
  45. Broderick JP, Brott TG, Duldner JE, et al. Volume of intracerebral hemorrhage (A powerful and easy-to-use predictor of 30-day mortality). Stroke. 1993;24:987–993
  46. Davis SM, Broderick J, Hennerici M, et al. Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175–1181
  47. Ruland SD, Gorelick PB. Stroke. Neurol Clin. 2008;26:871–1207
  48. Gorelick PB. Cerebral microbleeds (Evidence of heightened risk associated with aspirin use). Arch Neurol. 2009;66:691–693
  49. O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med. 2000;342:240–245
  50. Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68:116–121
  51. Flaherty ML, Tao H, Haverbusch M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008;71:1084–1089
  52. Zubkov AY, Mandrekar JN, Claasen DO, et al. Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol. 2008;65:1320–1325
  53. Steiner T, Diringer MN, Schneider D, et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery. 2006;59:767–773
  54. Broderick JP, Diringer MN, Hill MD, et al. Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke. 2007;38:1072–1075
  55. Wada R, Aviv RI, Fox AJ, et al. CT angiography “spot sign” predicts hematoma expansion in acute intracerebral hemorrhage. Stroke. 2007;38:1257–1262
  56. Goldstein JN, Fazen LE, Snider R, et al. Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology. 2007;68:889–894
  57. Sansing LH, Messe SR, Cucchiara BL, et al. The CHANT Investigators Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology. 2009;72:1397–1402
  58. Flibotte JJ, Hagan N, O'Donnell J, et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63:1059–1064
  59. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council; Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007;38:2001–2023
  60. Diringer MN. Intracerebral hemorrhage: pathophysiology and management. Crit Care Med. 1993;21:1591–1603
  61. Stochetti N, Maas AI, Chieregato A, et al. Hyperventilation in head injury: a review. Chest. 2005;127:1812–1827
  62. Powers WJ, Zazulia AR, Videen TO, et al. Autoregulation of cerebral blood flow surrounding acute (6-22 hours) intracerebral hemorrhage. Neurology. 2001;57:18–24
  63. Qureshi AI. Antihypertensive treatment of acute cerebral hemorrhage. Crit Care Med. 2009;(in press)
  64. Anderson CS, Huang Y, Wang JG, et al. INTERACT Investigators Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomized pilot trial. Lancet Neurol. 2008;7:391–399
  65. Potter JF, Robinson TG, Ford GA, et al. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol. 2009;8:48–56
  66. Claasen J, Jette N, Chum F, et al. Electrographic seizures and periodic discharges after intracerebral hemorrhage. Neurology. 2007;69:1356–1365
  67. Vespa PM, O'Phelan K, Shah M, et al. Acute seizures after intracerebral hemorrhage: a factor in progressive midline shift and outcome. Neurology. 2003;60:1441–1446
  68. Naidech AM, Garg RK, Liebling S, et al. Anticonvulsant use and outcomes after intracerebral hemorrhage. Stroke. 2009;40:3110–3115
  69. Szaflarski JP, Sangha KS, Lindsell CJ, et al. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care (in press).
  70. Mayer SA, Brun NC, Begtrup K, et al. Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators Recombinant activated factor IVV for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777–785
  71. Mayer SA, Brun NC, Begtrup K, et al. FAST Trial Investigators Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127–2137
  72. Goldstein JN, Rosand J, Schwamm LH. Warfarin reversal in anticoagulant-associated intracerebral hemorrhage. Neurocrit Care. 2008;9:277–283
  73. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc. 2007;82:82–92
  74. Mendelow AD, Gregson BA, Fernandes HM, et al. STICH Investigators Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomized trial. Lancet. 2005;365:387–397
  75. Surgical trial in intracerebral hemorrhage II. http://www.ncl.ac.uk/stich/Accessed November 9, 2009
  76. MIS+rtPA for ICH Evacuation (MISTIE). http://www.clinicaltrials.gov/ct2/show/NCT00224770Accessed November 19, 2009
  77. Bederson JB, Connolly ES, Batjer HH, et al. Guidelines for the management of aneurysm subarachnoid hemorrhage: a statement for healthcare professions from a special writing group of the stroke council, American Heart Association. Stroke. 2009;40:994–1025
  78. Bardach NS, Zhao S, Gress DR, et al. Association between subarachnoid hemorrhage outcomes and number of cases treated at California hospitals. Stroke. 2002;33:1851–1856
  79. Bassi P, Bandera R, Loiero M, et al. Warning signs in subarachnoid hemorrhage: a cooperative study. Acta Neurol Scand. 1991;84:277–281
  80. Kowalski RG, Claassen J, Kreiter KT, et al. Initial misdiagnosis and outcome after subarachnoid hemorrhage. JAMA. 2004;291:866–869
  81. Diringer MN. Management of aneurysmal subarachnoid hemorrhage. Crit Care Med. 2009;37:432–440
  82. Dupont SA, Wijdicks EFM, Manno EM, et al. Thunderclap headache and normal computed tomographic results: value of cerebrospinal fluid analysis. Mayo Clin Proc. 2008;83:1326–1331
  83. Ohkuma H, Tsurutani H, Suzuki S. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. Stroke. 2001;32:1176–1180
  84. Naidech AM, Bassin SL, Garg RK, et al. Cardiac troponin I and acute lung injury after subarachnoid hemorrhage. Neurocrit Care. 2009;11:177–182
  85. Vespa PM, Bleck TP. Neurogenic pulmonary edema and other mechanisms of impaired oxygenation after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2004;2:157–170
  86. Samuels MA. The brain-heart connection. Circulation. 2007;116:77–84
  87. Molyneaux A, Kerr RSC, Yu LM, et al. International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet. 2005;366:809–817
  88. Keyrouz SG, Diringer MN. Clinical review: prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11:220
  89. Carrera E, Schmidt JM, Oddo M, et al. Transcranial Doppler for predicting delayed cerebral ischemia after subarachnoid hemorrhage. Neurosurgery. 2009;65:316–324
  90. Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD000277. Review.PMID: 17636626 http://www.cochrane.org/reviews/en/ab000277.html
  91. Komotar RJ, Schmidt JM, Starke RM, et al. Resuscitation and critical care of poor grade subarachnoid hemorrhage. Neurosurgery. 2009;64:397–411
  92. Romero CM, Morales D, Reccius A, et al. Milrinone as a rescue therapy for symptomatic refractory cerebral vasospasm in aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2009;11:165–171
  93. Macdonald RL, Kassel NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1). Stroke. 2008;39:3015–3021
  94. Simvastatin in aneurysmal subarachnoid hemorrhage (STASH): a multicenter randomised controlled clinical trial. http://www.clinicaltrials.gov/ct2/show/NCT00731627Accessed November 22, 2009
  95. Harrigan MR. Endocrine and metabolic dysfunction syndromes in the critically ill. Crit Care Clin. 2001;17:125–138

PII: S0011-5029(09)00151-5

doi: 10.1016/j.disamonth.2009.12.003

Disease-A-Month
Volume 56, Issue 2 , Pages 72-100 , February 2010

Article Tools

* Image Usage & Resolution